Blake Insomnia Therapeutics has a patent pending compound, branded as Zleepax, that uses a beta blocker called Nebivolol as its primary ingredient, and the ingredient that helps to induce sleep, reports Equities.
Both Belsomra and E-2006, as well as a previous global bestseller, Lunesta, induce the residual daytime tiredness that Blake Insomnia Therapeutics is trying to overcome with Zleepax. The path to approval for these types of drugs is relatively long, but if Zleepax can successfully navigate through to regulatory approval in the US, and if it can pick up a label that states it removes the potential for residual tiredness, it could quickly start to eat away at the market share of the current leaders.
There are many risk factors for insomnia. Stress can be a significant factor. My experience suggests a distally displaced mandible pinches tissue and nerves in the posterior joint space.
When an advancing oral appliance is worn at night, these compressed and/or pinched tissues and nerves are more comfortable. This in turn allows sleep. This appliance carries no possible drug side effects. Providing such an appliance before drug use could be a preferred course of action.
Also these compressed tissues are made worse with a CPAP mask. The tight strap holding the mask in place pulls the jaw back. This increases the pressure in the posterior joint space and causes the patient to remove the mask during the night.